GlassScriptPhysician profile
Utpal K Bhatt
NPI 1649218983
$1,382.56
in general payments reported to CMS, 2019-2025
18 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $187 · 2021: $223 · 2022: $87.75 · 2023: $95.73 · 2024: $107 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $282.26 | 2019-2021 | |
| Insmed, INC. | $157.71 | 2019-2021 | |
| Glaxosmithkline, LLC. | $130.42 | 2023-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.75 | 2022-2025 | Ofev |
| Abbvie INC. | $97.76 | 2020-2022 | |
| Harmony Biosciences LLC | $96.19 | 2025 | |
| Allergan, INC. | $95.01 | 2019-2020 | |
| Shire North American Group INC | $92.79 | 2019 | |
| Inogen, INC. | $79.88 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Gilead Sciences, INC. | $47.68 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $35.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.80 | 2023 | Farxiga, Symbicort |
| Merck Sharp & Dohme LLC | $26.75 | 2024 | Keytruda |
| Shionogi INC | $24.99 | 2021 | |
| Janssen Scientific Affairs, LLC | $23.71 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $20.76 | 2025 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $18.21 | 2019 | |
| Inspire Medical Systems, INC. | $17.90 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Utpal Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.